CClinicalTrials.gg
TerminatedNCT03339388Updated Apr 17, 2024

Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease

An interventional study of Enhanced Lithotripsy System in Urinary Stone, sponsored by Avvio Medical. Terminated at 4 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Avvio Medical · Not applicable, Interventional, and Device feasibility

Why this study was terminated
Adequate enrollment has been achieved
Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeal lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones.

Read the detailed description

This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeal lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones. Subjects will be treated up to 2 times with the Enhanced Lithotripsy System and followed for 90 days after the last treatment session.

02

Conditions studied

  • Urinary Stone

Keywords

  • lithotripsy
  • urinary stone
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female aged ≥ 18 years to ≤ 75 years.
  • One urinary stone-apparent on a computed tomography (CT) scan within 14 days prior to study enrollment
  • Stone size, as estimated by pre-procedure CT, with all dimensions 15 mm or less.
  • Provides written informed consent
  • Understands and accepts the study requirements

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years of age or over 75 years of age
  • Diagnosis of radiolucent stones
  • Diagnosis of stones in the lower pole of kidney
  • History of cystinuria
  • Urine pH below 5.5
  • Current untreated urinary tract infection
  • Pregnancy
  • Coagulation abnormality or taking prescription anticoagulants. Aspirin usage will be discontinued at least 7 days prior to enrollment at the discretion of the attending physician.
  • Mobility issues - unable to comfortably lie still for up to 30 minutes or unable to roll from back to side
  • Known hypersensitivity to conductivity gel
  • Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)
  • Body mass index greater than 35
  • American Society of Anesthesiologists (ASA) score of 3 or greater general anesthesia risk level
  • Known sensitivity to possible medications used before, during, or after the ELS procedure, including but not limited to the following: sedative agents, general anaesthetics, topical anaesthetics, and opioid analgesics.
  • Enrollment in another research study or previous participation within 30 days of enrollment.
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Enhanced Lithotripsy System

    Treatment of urinary stones with the Enhanced Lithotripsy System

    Device: Enhanced Lithotripsy System

Interventions

  • DeviceEnhanced Lithotripsy System

    Stone treatment with the Enhanced Lithotripsy System

05

What researchers measure

Primary outcomes

  1. Proportion of study participants with Serious Device and/or Serious Procedure-Related Adverse Events (Safety)

    Incidence of Serious Device and/or Serious Procedure-Related adverse events

    Time frame: 90 days

Secondary outcomes

  1. Stone-free status

    Proportion of study participants who are successfully treated \[absence of stones or with only clinically-insignificant remaining fragments\]

    Time frame: 30 days

Other outcomes

  1. Pain medication usage

    Collection of pain concomitant pain medications

    Time frame: 30 days

  2. Time to stone passage

    Evaluation of stone presence

    Time frame: 30 days

  3. Pain scoring

    Patient reported pain scores

    Time frame: 30 days

06

Study locations

4 sites
  • McArthur Urology
    Campbelltown, New South Wales 2560, Australia
  • Westmead Private Hospital
    Westmead, New South Wales 2145, Australia
  • Goldfields Urology
    Bendigo, Victoria 3550, Australia
  • Austin Health
    Melbourne, Victoria 3084, Australia
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03339388
Lead sponsor
Avvio Medical
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Dec 8, 2017
Primary completion
Jul 10, 2018
Completion
Oct 5, 2022
Last update
Apr 17, 2024

Study contacts

Damien M Bolton, MD, MBBS
principal investigator · Austin Hospital, Melbourne Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion